Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New glasses could help Kids' eyesight stop getting worse

NCT ID NCT05562622

Disease control Sponsor: SightGlass Vision, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This trial tests whether special spectacle lenses called Diffusion Optics Technology (DOT) lenses can slow the progression of nearsightedness (myopia) in Chinese children aged 6 to 13. Over 12 months, 195 children will wear either the DOT lenses or standard single-vision lenses. The main goal is to see if the DOT lenses reduce the lengthening of the eye, which is linked to worsening myopia.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Diffusion Optics Technology (DOT) spectacle lenses
What this could lead to
If successful, these lenses could offer a simple, non-invasive way to slow the progression of nearsightedness in children, reducing the need for stronger prescriptions over time.
What could go wrong
This is a 12-month study with 195 children, so results are still early. The lenses may not work for everyone, and long-term benefits beyond one year are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

195 people

The number who actually took part.

Started

Feb 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 13 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Children 6-13 years of age 2. SER error between -0.75D and -5.00D 3. Willingness to wear study spectacles and participate in the trial for 12 months without contact lens wear Exclusion Criteria: 1. Prior usage of atropine, multifocal contact lenses, or orthokeratology (ortho-K) 2. Astigmatism worse than -1.50 DC (by manifest refraction) in either eye 3. Anisometropia (SER manifest refraction) greater than 1.00 D

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juvenile myopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

myopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Juvenile myopia Myopia

Contacts and locations

Locations

  • Aier Eye Hospital

    Changsha, China

  • Fudan University EENT

    Shanghai, China

  • Tianjin Eye Hospital

    Tianjin, China

  • West China Hospital

    Chengdu, China

  • Zhongshan Ophthalmic Center

    Guangzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.